초록 ▼

The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs

The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (짹)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

대표청구항 ▼

What is claimed is: 1. A compound of Formula (I): or pharmaceutically acceptable salts, hydrates or solvates thereof, wherein: R1 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, subst

What is claimed is: 1. A compound of Formula (I): or pharmaceutically acceptable salts, hydrates or solvates thereof, wherein: R1 is selected from the group consisting of acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl; R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl or optionally, R2 and R3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring; R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or trialkylsilyl; and R5 is selected from the group consisting of substituted aryl, heteroaryl and substituted heteroaryl. 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle. 3. The composition of claim 2, comprising an oral dosage form. 4. The composition of claim 3, wherein the oral dosage form is a sustained release oral dosage form. 5. The composition of claim 4, wherein the dosage form is adapted to be swallowed by a patient in order to introduce the dosage form into an intestinal lumen of the patient; the dosage form further being adapted to release the compound of claim 1 gradually into the intestinal lumen of the patient over a period of hours after said swallowing, the gradual release causing the compound of claim 1 to be cleaved after said swallowing to provide a therapeutic concentration the compound of claim 1 in the plasma of the patient. 6. The composition of claim 5 wherein the period of hours comprises at least about 6 hours. 7. The composition of claim 5, wherein the period of hours comprises at least about 8 hours. 8. The composition of claim 5, wherein the period of hours comprises at least about 12 hours.